Business
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Metastatic Breast Cancer Study
[IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell&...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study\n\n\n\n\n\n\n [IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS in Phase 1/2a study\n \n\n\n\n\n\n No treatment limited toxicities observed\n \n\n\n\n\n\n Patient remains on study with stable disease elsewhere\n \n\n\n\n\n\n\n PHILADELPHIA and VANCOUVER, British Columbia, July 09, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS, the Company’s personalized off the shelf immunotherapy.\n \n\n BriaCell’s first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung metastasis following four doses of BriaCell’s Bria-OTS monotherapy. The complete response was first observed at two months (\n \n previously reported\n \n ) and confirmed at four (\n \n previously reported\n \n ) and now six months. The patient has been dosed with 12 cycles of Bria-OTS to date.\n \n\n\n Figure 1: Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the right lung of the metastatic breast cancer (MBC) patient following 2 months of therapy and confirmed at 4, and 6 months of therapy\n \n\n\n 1\n \n\n\n (axial and coronal views)\n \n\n\n\n\n\n\n\n\n “These results represent an exciting clinical milestone in the Bria-OTS program,” stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, CA, and Principal Investigator for the Bria-OTS study. “We are seeing strong single agent activity in a very challenging population and are eager to explore this approach across more patient subtypes and tumors.”\n \n\n “We are highly encouraged by this remarkable and durable clinical response, especially at the lowest dose level,” added Dr. William V. Williams, BriaCell’s President and CEO. “This data...